Researchers have discovered that a drug designed to treat Celiac disease supported a more rapid return to normal activities for patients following COVID. A small, randomized clinical trialfound the oral drug larazotide was both safe and effective in treating children with MIS-C.
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.